Endocrine Abstracts

Introduction: Everolimus is a drug selective inhibitor of mTOR and approved by the FDA in 2011 for treatment of neuroendocrine tumors of pancreatic origin unresectable. Our objective was to evaluate the efficacy and safety of everolimus in a patient with malignant pancreatic head insulinoma.Case: This is a 31 year old man who complains of epigastric pain, dizziness, sweating and syncope related to exercise. During admission is objectively severe hypoglyc...

Introduction and objectives: Multiple surgeries are associated with many complications in the local recurrence of papillary thyroid carcinoma. Our objective is to evaluate the efficiency of the enolization in the recurrent metastatic cervical lymph nodes in patients with limited nodal disease.Material and methods: We studied 13 patients (six males and seven females) with a mean age of 43±14.4 years with papillary thyroid carcinoma intervened (total ...